EAST WINDSOR, N.J. & OXFORD, England--(BUSINESS WIRE)--Aestus Therapeutics, Inc. and Prosidion Ltd., a wholly owned subsidiary of Astellas Pharma Inc., announced today a license agreement providing Aestus with exclusive, world-wide rights to the Prosidion investigational product PSN-357. Aestus will develop the product as ATx09-002, a novel, first-in-class therapeutic for the treatment of neuropathic pain.
